<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Regulatory Affairs on The Coders Blog</title><link>https://thecodersblog.com/categories/regulatory-affairs/</link><description>Recent content in Regulatory Affairs on The Coders Blog</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Mon, 11 May 2026 17:29:19 +0000</lastBuildDate><atom:link href="https://thecodersblog.com/categories/regulatory-affairs/index.xml" rel="self" type="application/rss+xml"/><item><title>FDA Accelerates Oversight: One-Day Inspections to Bolster MedTech Safety</title><link>https://thecodersblog.com/fda-launches-one-day-inspectional-assessments-2026/</link><pubDate>Mon, 11 May 2026 17:29:19 +0000</pubDate><guid>https://thecodersblog.com/fda-launches-one-day-inspectional-assessments-2026/</guid><description>&lt;p&gt;The silent hum of a manufacturing floor, a symphony of precision engineering, can quickly turn into a discordant alarm bell. Imagine this: a routine FDA inspection, anticipated to be a brief, standard check, instead reveals a critical non-compliance issue. This oversight, missed due to the sheer volume of data or inherent limitations in prior risk assessment, escalates into a full-blown investigation, product recall, or worse, a patient safety incident. This isn&amp;rsquo;t a hypothetical dystopia; it&amp;rsquo;s the acute risk facing MedTech companies if regulatory oversight mechanisms fail to keep pace with the industry&amp;rsquo;s complexity and speed. The U.S. Food and Drug Administration (FDA) is now proactively addressing this very tension with the launch of a pilot program for &amp;ldquo;one-day inspectional assessments.&amp;rdquo; This initiative signals a significant pivot towards more agile, data-driven, and targeted oversight, aiming to bolster MedTech safety by enhancing compliance monitoring in real-time.&lt;/p&gt;</description></item></channel></rss>